Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acomplia Pricing Likely To Follow Statin Model, Sanofi Says

Executive Summary

Sanofi is likely to price the weight loss/smoking cessation agent Acomplia on par with the daily cost of statin therapy, the company suggested during an Aug. 31 analyst call

You may also be interested in...



Sanofi-Aventis Acomplia Faces Good Reception From Physicians And Payers

Acomplia'schances of gaining acceptance as treatment for metabolic syndrome are improved by its effects on a range of the disease's comorbidities, according to Decision Resources analyst Donny Wong

Sanofi-Aventis Acomplia Faces Good Reception From Physicians And Payers

Acomplia'schances of gaining acceptance as treatment for metabolic syndrome are improved by its effects on a range of the disease's comorbidities, according to Decision Resources analyst Donny Wong

Sanofi Feels The Weight Of FDA’s “Approvable” Letter For Rimonabant

FDA is not requesting additional clinical trials for Acomplia's weight loss indication, Sanofi-Aventis said Feb. 24 during its investors meeting in Paris

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel